Compare Essex Property Trust, Inc. (ESS) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs Travere Therapeutics Inc. Common Stock — how do they compare? Essex Property Trust, Inc. trades at $268.84 (market cap $17.47B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Essex Property Trust, Inc. is far larger — about 3.6× Travere Therapeutics Inc. Common Stock's market cap, and Essex Property Trust, Inc. pays a 3.81% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Essex Property Trust, Inc. for 112 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| ESS | TVTX | |
|---|---|---|
Market Cap | $17.47B | $4.88B |
Volume | 425,157 | 1,668,577 |
Sector | Real Estate | Health |
52-Week High | $298.33 | $67.52 |
52-Week Low | $239.61 | $26.79 |
Typical Hold Time | 112 Days | 0 Days |
Enterprise Value | $24.07B | $5.01B |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESS trades at $269.37, down 0.38% with neutral technical signals. The company shows strong profitability with 67.9% gross margins and 21.48% net income, though recent earnings were mixed with Q2 2026 missing expectations. Revenue growth has been steady, reaching $1.89B in 2025. Analyst consensus is mixed with 38.3% buy ratings and a $300.77 price target, representing 11.7% upside. Recent news highlights strong Q2 results and legal resolution.
ESS offers solid fundamentals with premium valuation (P/E 42.35) and strong operational efficiency. Key risks include earnings volatility and high debt levels ($6.46B long-term). The stock presents opportunity from raised guidance and institutional interest, but requires monitoring of West Coast real estate market conditions and interest rate sensitivity.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
